Drugs / ABP 654
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04761627 | Mar 2021 → Feb 2023 | psoriasis | Amgen | Completed | Met primary |
| Phase 3 | NCT04607980 | Nov 2020 → Jan 2022 | psoriasis | Amgen | Completed | Met primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2022-04-18 | Amgen | Results AMGEN ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 3 STUDY OF ABP 654, BIOSIMILAR CANDIDATE TO STELARA® (USTEKINUMAB) amgen.com ↗
The study met the primary efficacy endpoint, demonstrating no clinically meaningful differences between ABP 654 and STELARA. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-04-18 | Amgen | AMGEN ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 3 STUDY OF ABP 654, BIOSIMILAR CANDIDATE TO STELARA® (USTEKINUMAB) amgen.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABP 654 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04607980 ↗ |
| Modality | Protein / enzyme biologic | “ABP 654 is a biosimilar to ustekinumab reference product (RP).” PMID 39442018 ↗ Apr 2025 |
| Route | Subcutaneous | “Participants will receive SC injection of ABP 654.” NCT04607980 ↗ |